Table 3.
Assessment of comparative safety of systemic and low‐bioavailability corticosteroids in inflammatory bowel diseases
| SUCRA value (%) | Probability best (%) | Mean rank | |
|---|---|---|---|
| A. Treatment discontinuations or withdrawals from the study due to adverse events | |||
| PBO | 40.2 | 2.3 | 3.4 |
| B‐MMX | 51.4 | 9.8 | 2.9 |
| BUD | 27.6 | 2.3 | 3.9 |
| BDP | 87.4 | 77.7 | 1.5 |
| PRED | 43.5 | 7.9 | 3.3 |
| B. Serious adverse events | |||
| PBO | 66.1 | 27.7 | 2.4 |
| B‐MMX | 35.7 | 10.1 | 3.6 |
| BUD | 56.7 | 12.0 | 2.7 |
| BDP | 25.5 | 20.6 | 4.0 |
| PRED | 66.0 | 29.6 | 2.4 |
| C. Corticosteroid‐related adverse events | |||
| PBO | 85.8 | 44.4 | 1.6 |
| B‐MMX | 86.6 | 54.2 | 1.5 |
| BUD | 48.9 | 0.2 | 3.0 |
| BDP | 23.1 | 1.3 | 4.1 |
| PRED | 5.6 | 0.0 | 4.8 |
Herein we present the SUCRA values providing the hierarchy of the competing treatments, the estimated probabilities of each treatment being the best, and the mean ranking of each treatment using 10 000 draws.
BDP, beclomethasone dipropionate; BUD, budesonide; B‐MMX, budesonide MMX; IBD, inflammatory bowel disease; PBO, placebo; PRED, prednisone/prednisolone.